Nanoparticle-mediated drug delivery system for atherosclerotic cardiovascular disease

Tetsuya Matoba, Jun ichiro Koga, Kaku Nakano, Kensuke Egashira, Hiroyuki Tsutsui

Research output: Contribution to journalReview article

14 Citations (Scopus)

Abstract

Administration of drugs and other therapeutic agents has been the central strategy of contemporary medicine for cardiovascular disease. The use of drug delivery systems (DDS) includes micelles, liposomes, polymeric nanoparticles, dendrimers, carbon nanotubes, and crystalline metals. Nano-DDS modify in vivo drug kinetics, depending on (patho)physiological mechanisms such as retard excretion, vascular permeability, and incorporation by mononuclear phagocyte systems, which constitute the ‘passive-targeting’ property of nano-DDS. These properties of nano-DDS are applicable to inflammatory diseases including atherosclerosis. Atherosclerotic plaque destabilization and rupture account for the majority of acute myocardial infarction, for which inflammatory monocytes and macrophages play critical roles. In our experience, polymeric nanoparticles have been delivered to inflammatory monocytes and macrophages in an atherosclerotic mouse model. Nano-DDS loaded with pioglitazone reduced Ly6Chigh inflammatory monocytes and increased Ly6Clow non-inflammatory monocytes in the peripheral blood, and induced M2 macrophage-associated genes in the aorta. Pioglitazone-nanoparticles finally stabilized atherosclerotic plaques assessed by a decrease in the number of buried fibrous caps in the plaque. Application of nano-DDS is a unique and promising approach to prevent life-threatening cardiovascular events including acute myocardial infarction by regulating inflammation in the cardiovascular system.

Original languageEnglish
Pages (from-to)206-211
Number of pages6
JournalJournal of Cardiology
Volume70
Issue number3
DOIs
Publication statusPublished - Sep 1 2017

Fingerprint

Drug Delivery Systems
Nanoparticles
Cardiovascular Diseases
pioglitazone
Monocytes
Macrophages
Atherosclerotic Plaques
Myocardial Infarction
Dendrimers
Mononuclear Phagocyte System
Carbon Nanotubes
Capillary Permeability
Micelles
Cardiovascular System
Liposomes
Aorta
Rupture
Atherosclerosis
Pharmacokinetics
Metals

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Nanoparticle-mediated drug delivery system for atherosclerotic cardiovascular disease. / Matoba, Tetsuya; Koga, Jun ichiro; Nakano, Kaku; Egashira, Kensuke; Tsutsui, Hiroyuki.

In: Journal of Cardiology, Vol. 70, No. 3, 01.09.2017, p. 206-211.

Research output: Contribution to journalReview article

@article{97855d43c6e84d108c94ac0e564e549c,
title = "Nanoparticle-mediated drug delivery system for atherosclerotic cardiovascular disease",
abstract = "Administration of drugs and other therapeutic agents has been the central strategy of contemporary medicine for cardiovascular disease. The use of drug delivery systems (DDS) includes micelles, liposomes, polymeric nanoparticles, dendrimers, carbon nanotubes, and crystalline metals. Nano-DDS modify in vivo drug kinetics, depending on (patho)physiological mechanisms such as retard excretion, vascular permeability, and incorporation by mononuclear phagocyte systems, which constitute the ‘passive-targeting’ property of nano-DDS. These properties of nano-DDS are applicable to inflammatory diseases including atherosclerosis. Atherosclerotic plaque destabilization and rupture account for the majority of acute myocardial infarction, for which inflammatory monocytes and macrophages play critical roles. In our experience, polymeric nanoparticles have been delivered to inflammatory monocytes and macrophages in an atherosclerotic mouse model. Nano-DDS loaded with pioglitazone reduced Ly6Chigh inflammatory monocytes and increased Ly6Clow non-inflammatory monocytes in the peripheral blood, and induced M2 macrophage-associated genes in the aorta. Pioglitazone-nanoparticles finally stabilized atherosclerotic plaques assessed by a decrease in the number of buried fibrous caps in the plaque. Application of nano-DDS is a unique and promising approach to prevent life-threatening cardiovascular events including acute myocardial infarction by regulating inflammation in the cardiovascular system.",
author = "Tetsuya Matoba and Koga, {Jun ichiro} and Kaku Nakano and Kensuke Egashira and Hiroyuki Tsutsui",
year = "2017",
month = "9",
day = "1",
doi = "10.1016/j.jjcc.2017.03.005",
language = "English",
volume = "70",
pages = "206--211",
journal = "Journal of Cardiology",
issn = "0914-5087",
number = "3",

}

TY - JOUR

T1 - Nanoparticle-mediated drug delivery system for atherosclerotic cardiovascular disease

AU - Matoba, Tetsuya

AU - Koga, Jun ichiro

AU - Nakano, Kaku

AU - Egashira, Kensuke

AU - Tsutsui, Hiroyuki

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Administration of drugs and other therapeutic agents has been the central strategy of contemporary medicine for cardiovascular disease. The use of drug delivery systems (DDS) includes micelles, liposomes, polymeric nanoparticles, dendrimers, carbon nanotubes, and crystalline metals. Nano-DDS modify in vivo drug kinetics, depending on (patho)physiological mechanisms such as retard excretion, vascular permeability, and incorporation by mononuclear phagocyte systems, which constitute the ‘passive-targeting’ property of nano-DDS. These properties of nano-DDS are applicable to inflammatory diseases including atherosclerosis. Atherosclerotic plaque destabilization and rupture account for the majority of acute myocardial infarction, for which inflammatory monocytes and macrophages play critical roles. In our experience, polymeric nanoparticles have been delivered to inflammatory monocytes and macrophages in an atherosclerotic mouse model. Nano-DDS loaded with pioglitazone reduced Ly6Chigh inflammatory monocytes and increased Ly6Clow non-inflammatory monocytes in the peripheral blood, and induced M2 macrophage-associated genes in the aorta. Pioglitazone-nanoparticles finally stabilized atherosclerotic plaques assessed by a decrease in the number of buried fibrous caps in the plaque. Application of nano-DDS is a unique and promising approach to prevent life-threatening cardiovascular events including acute myocardial infarction by regulating inflammation in the cardiovascular system.

AB - Administration of drugs and other therapeutic agents has been the central strategy of contemporary medicine for cardiovascular disease. The use of drug delivery systems (DDS) includes micelles, liposomes, polymeric nanoparticles, dendrimers, carbon nanotubes, and crystalline metals. Nano-DDS modify in vivo drug kinetics, depending on (patho)physiological mechanisms such as retard excretion, vascular permeability, and incorporation by mononuclear phagocyte systems, which constitute the ‘passive-targeting’ property of nano-DDS. These properties of nano-DDS are applicable to inflammatory diseases including atherosclerosis. Atherosclerotic plaque destabilization and rupture account for the majority of acute myocardial infarction, for which inflammatory monocytes and macrophages play critical roles. In our experience, polymeric nanoparticles have been delivered to inflammatory monocytes and macrophages in an atherosclerotic mouse model. Nano-DDS loaded with pioglitazone reduced Ly6Chigh inflammatory monocytes and increased Ly6Clow non-inflammatory monocytes in the peripheral blood, and induced M2 macrophage-associated genes in the aorta. Pioglitazone-nanoparticles finally stabilized atherosclerotic plaques assessed by a decrease in the number of buried fibrous caps in the plaque. Application of nano-DDS is a unique and promising approach to prevent life-threatening cardiovascular events including acute myocardial infarction by regulating inflammation in the cardiovascular system.

UR - http://www.scopus.com/inward/record.url?scp=85017453834&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017453834&partnerID=8YFLogxK

U2 - 10.1016/j.jjcc.2017.03.005

DO - 10.1016/j.jjcc.2017.03.005

M3 - Review article

AN - SCOPUS:85017453834

VL - 70

SP - 206

EP - 211

JO - Journal of Cardiology

JF - Journal of Cardiology

SN - 0914-5087

IS - 3

ER -